Because the increasing use of PSMA-targeted PET/CT in prostate cancer is likely to be associated with greater use in earlier stages of BCR, it is important to characterize further 68Ga-PSMA-11 PET/CT performance in the very low PSA BCR setting. The gene discussed is BCR; the disease is prostate cancer.